Felicia Yarde, M.D., Marlies Voorhuis, M.D., Madeleine Dólleman, M.D., Erik A.H. Knauff, M.D., Ph.D., Marinus J.C. Eijkemans, M.Sc., Frank J.M. Broekmans, M.D., Ph.D.
Volume 100, Issue 3, Pages 831-838.e2, September 2013
To investigate the role of serum antimüllerian hormone (AMH) as a predictor of live birth and reproductive stage in subfertile women with elevated basal FSH levels.
A prospective observational cohort study conducted between February 2005 and June 2009.
Tertiary fertility center.
Subfertile women with  a regular menstrual cycle (mean cycle length 25–35 days);  basal FSH concentrations ≥12.3 IU/L; and  younger than 40 years (n = 96).
Main Outcome Measure(s):
Live birth and reproductive stage according to the Stages of Reproductive Aging Workshop.
A cumulative live birth rate of 63.5% was observed during a median follow-up of 3.3 years (n = 85). The AMH level was significantly associated with live birth. There was evidence of a nonlinear prediction pattern, with an increase in chances of live birth until an AMH level of 1 μg/L. Other ovarian reserve tests and chronological age appeared of limited value in predicting live birth. In addition, AMH was significantly associated with the timing of reproductive stages (n = 68) (i.e., the occurrence of menopausal transition or menopause during follow-up).
The present findings suggest applicability of AMH determination as a marker for actual fertility in subfertile women with elevated basal FSH levels.
Read the full text at: http://www.fertstert.org/article/S0015-0282(13)00607-9/fulltext